Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Report library

Report library


  • Sort by Custom
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Vasotec

    Read More

    Vasotec’s (enalapril; Merck & Co/Valeant) role in chronic heart failure (CHF) is severely limited by

    competition from generic equivalents.

    August 2, 2016
    Find out more
  • VB-111

    Read More

    VB-111 (VBL Therapeutics) will be able to succeed in the US as an add-on therapy to Avastin

    (bevacizumab; Genentech/Roche/Chugai) in the second-line of therapy, should it present positive data

    from the Phase III GLOBE study.

    April 13, 2016
    Find out more
  • Vectibix

    Read More

    Vectibix (panitumumab; Amgen/Takeda) is a fully human immunoglobulin G2 monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR).

    December 11, 2017
    Find out more
  • Velcade

    Read More

    Velcade (bortezomib; Takeda/Johnson & Johnson) is an intravenously or subcutaneously administered 26S proteasome inhibitor that affects multiple signaling cascades and induces cell death.

    August 9, 2018
    Find out more
  • Veliparib

    Read More

    Veliparib is a small-molecule poly (ADP-ribose) polymerase (PARP) inhibitor being developed by AbbVie. PARP is an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events.

    February 26, 2020
    Find out more
  • Venclexta_report

    Venclexta

    Read More

    Venclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell lymphoma-2 (BCL-2) family of proteins.

    January 31, 2019
    Find out more
  • Venetoclax

    Read More

    Venetoclax (AbbVie/Roche) is a novel B-cell lymphoma-2 (BCL-2) inhibitor currently being developed

    for treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL).

    September 11, 2015
    Find out more
  • Venofer

    Read More

    Venofer (poly-nuclear iron (III)-hydroxide in sucrose; Vifor/Luitpold Pharmaceuticals) is an iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease.

    January 11, 2018
    Find out more
  • Vericiguat

    Read More

    Vericiguat is a first-in-class soluble guanylate cyclase (sGC) stimulator that acts to increase levels of cyclic guanosine monophosphate (cGMP) via the nitric oxide-sGC-cGMP pathway.

    December 11, 2017
    Find out more
  • Vertex triple combinations

    Read More

    Vertex is developing several triple combination regimens in order to further its cystic fibrosis portfolio with the best such regimen, combining a new CFTR corrector compound

    September 3, 2018
    Find out more
  • Verubecestat

    Read More

    Verubecestat’s (Merck & Co) Phase Ib studies revealed highly impressive results in its capability to

    almost abolish cerebrospinal fluid (CSF) amyloid-beta fragments.

    September 2, 2016
    Find out more
  • Vibativ

    Read More

    Vibativ is a lipoglycopeptide antibiotic that is a semisynthetic derivative of vancomycin. The drug exhibits a dual bactericidal mechanism of action.

    September 10, 2014
    Find out more
  • Victoza

    Read More

    Victoza (liraglutide; Novo Nordisk) is a member of the glucagon-like peptide-1 (GLP-1) agonist class. GLP-1 agonists are incretin mimetics, mimicking the endogenous gut hormone GLP-1, which stimulates insulin-secreting beta cells in the pancreas.

    July 7, 2017
    Find out more
  • Viekira Pak franchise

    Read More

    AbbVie’s Viekira Pak franchise comprises Viekira Pak ([paritaprevir + ritonavir + ombitasvir] + dasabuvir), Viekira XR ([paritaprevir + ritonavir + ombitasvir + dasabuvir]), and Technivie ([paritaprevir + ritonavir + ombitasvir]), which is branded as Viekirax outside the US market.

    November 6, 2017
    Find out more
  • Vigil

    Read More

    Vigil (Gradalis) is an autologous tumor-based vaccine incorporating a plasmid encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a novel.

    October 30, 2015
    Find out more
Page 81 of 85
Page 81 of 85«‹7980818283›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top